ARTICLES LIST

Clear Search

Select the Article Source National Cancer Institute Office of Dietary Supplements National Institute on Aging Healthfinder.gov National Institute of Child Health and Human Development Centers for Disease Control and Prevention Administration for Children and Families National Institute of Environmental Health Sciences National Library of Medicine National Institute of Allergy and Infectious Diseases National Center for Complementary and Integrative Health National Institute of Neurological Disorders and Stroke NIH Senior Health National Institute of Arthritis and Musculoskeletal and Skin Diseases Health and Human Services National Institute of General Medical Sciences National Institute of Dental and Craniofacial Research National Human Genome Research Institute Food and Drug Administration Center for Tobacco Products Public Health and Medical Emergency Support for a Nation Prepared Office of Disease Prevention and Health Promotion, Healthy People National Institute on Drug Abuse National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases U S Food and Drug Administration National Institute on Deafness and Other Communication Disorders National Heart, Lung, and Blood Institute

Media ID	Source Name	Media Type	Language	Media Name	Media Description	Keywords	Keywords	Link to Article
1492	National Cancer Institute	Html	en	Childhood Acute Lymphoblastic Leukemia Treatment (PDQ®)–Health Professional Version	For acute lymphoblastic leukemia (ALL), the 5-year survival rate rose from 60% to about 90% for children younger than 15 years and from 28% to about 75% for adolescents aged 15–19 years between 1975 and 2010. Get information about risk factors, signs, diagnosis, genomics, survival, risk-based treatment assignment, and induction and postinduction therapy for children and adolescents with newly diagnosed and recurrent ALL.	prognostic factors 0.457078 B-Cell Acute Lymphoblastic 0.477707 Cancer Statistics Review 0.442138 B-acute lymphoblastic leukemia 0.487736 Leukemia Group 0.457445 children 0.485859 childhood lymphoblastic leukaemia 0.461366 acute lymphoblastic leukaemia 0.619966 acute lymphoblastic leukemias 0.490719 leukemia cells. 0.443609 prognostic significance 0.464566 Nat Genet 0.45804 leukemia susceptibility gene 0.452718 Hyperdiploid leukemia cells 0.447496 et al. 0.591777 SEER Cancer Statistics 0.449829 lymphoblastic leukemia consortium 0.485454 childhood acute leukemias 0.444646 frank leukemia 0.449613 Br J Haematol 0.473302 early T-cell precursor 0.46793 PUBMED Abstract 0.469887 concordant leukemia 0.449352 residual leukemia 0.447727 Pediatr Blood Cancer 0.49042	acute lymphocytic leukemia 0.489397 Leukemia Study Group 0.454229 National Cancer Institute 0.475056 acute lymphoblastic leukaemias 0.494907 childhood leukemia 0.453157 outcome 0.442439 myeloid leukemia stem 0.447271 lymphoblastic leukemia risk 0.49811 lymphoblastic leukaemia aetiology 0.462653 childhood 0.471724 Abstract 0.585405 Acute leukaemia 0.444978 cancer group 0.443895 Pediatr Hematol Oncol 0.438989 Clin Oncol 0.520227 Pediatric Oncology Group 0.440216 infant leukemia 0.443122 acute promyelocytic leukemia 0.469574 acute lymphoblastic leukemia 0.925289 acute leukemia 0.478163 Lymphoblastic Leukemia Treated 0.486039 Children Leukemia Group 0.457299 leukemia cells 0.45331 oncology group 0.497434	CLICK HERE
1536	National Cancer Institute	Html	en	Laetrile/Amygdalin (PDQ®)–Health Professional Version	Expert-reviewed information summary about the use of laetrile/amygdalin as a treatment for people with cancer.	cancer treatment 0.52441 cancer cell inhibitors. 0.542345 intravenous amygdalin treatment 0.677872 amygdalin occurs 0.621015 potential anticancer activity 0.529695 cyanide poisoning 0.73495 blood cyanide levels 0.657623 intestinal bacteria 0.607185 primordial germ cells 0.521102 purported anticancer activity 0.532782 oral amygdalin 0.650441 cancer patients 0.590892 complete responses 0.526167 high-dose vitamin supplements 0.5155 metabolic therapy 0.516142 U.S.-patented Laetrile 0.757295 laetrile therapy 0.736124 amygdalin interacts 0.616968 laetrile’s breakdown 0.71917 laetrile practitioners. 0.705315 anticancer activity 0.587095 nontoxic intravenous form 0.531127 specific anticancer properties 0.534462 intravenous Laetrile 0.740226 United States 0.629681	positive results 0.563482 case series 0.523576 cancer cells 0.637689 oral maintenance therapy 0.601513 colon cancer cells 0.550218 promising cancer therapies 0.544057 term laetrile 0.84507 human breast cancer 0.525831 laetrile treatment. 0.765844 higher-dose amygdalin therapy 0.65865 National Cancer Institute 0.610445 cyanide anion 0.594345 partial responses 0.519394 Laetrile supporters 0.777243 term vitamin B-17 0.520783 amygdalin 0.757648 enzyme beta-glucosidase 0.562945 anticancer agent 0.587895 case reports 0.550533 hydrogen cyanide 0.876372 cyanide group 0.578561 laetrile 0.994496 chemical amygdalin 0.642935 cancer 0.720035	CLICK HERE
1544	National Cancer Institute	Html	en	Adult Acute Myeloid Leukemia Treatment (PDQ®)–Patient Version	Expert-reviewed information summary about the treatment of adult acute myeloid leukemia.	adult aml 0.716289 red blood cells 0.594071 cancer treatment 0.467513 blood -forming cells 0.4491 acute myeloblastic leukemia 0.44585 acute myelogenous leukemia 0.445245 chemotherapy 0.473847 PDQ cancer information 0.503817 white blood cells 0.675945 clinical trials 0.938073 mature blood cells 0.50039 cancer information summary 0.459101 clinical trial 0.615294 stem cells 0.519631 stem cell transplant 0.480735 acute granulocytic leukemia 0.446114 Myeloid Leukemia Treatment 0.448761 blood cells 0.735668 radiation therapy 0.468603 treatment 0.673705 myeloid stem cell 0.438755 stored stem cells 0.437216 immature blood cells 0.448693 arsenic trioxide 0.473356	cancer cells 0.602593 specific cancer cells 0.456728 recurrent adult aml 0.474546 untreated adult aml 0.465491 acute myeloid leukemia 0.930922 stem cell 0.533281 treatment clinical trials 0.44329 blood stem cells 0.488116 National Cancer Institute 0.460343 spinal cord 0.512703 normal cells 0.467456 myeloid stem cells 0.482174 new treatment 0.480473 white blood cell 0.463646 combination chemotherapy 0.472241 bone marrow 0.747056 cells 0.827248 acute promyelocytic leukemia 0.5928 cancer clinical trials 0.452604 acute nonlymphocytic leukemia 0.445812 acute lymphoblastic leukemia 0.434651 acute leukemia 0.43925 cancer 0.808047 standard treatment 0.467846	CLICK HERE
1565	National Cancer Institute	Html	null	Lip and Oral Cavity Cancer Treatment (PDQ®)–Patient Version	Expert-reviewed information summary about the treatment of lip and oral cavity cancer.			CLICK HERE
1792	National Cancer Institute	Html	es	Náuseas y vómitos relacionados con el tratamiento del cáncer (PDQ®)–Versión para pacientes	Resumen de información revisada por expertos acerca de las náuseas y vómitos como complicaciones del cáncer o su tratamiento. Se plantean abordajes de tratamiento de las náuseas y vómitos.	radioterapia nombre 0.366149 Dexametasona Corticosteroides 0.345517 palonosetrón antagonistas 0.420992 siguientes tipos 0.357417 siguientes estrategias 0.348254 único signo 0.33198 causa náuseas 0.753796 National Cancer Institute 0.339057 determinados medicamentos 0.5578 siguientes riesgos 0.330997 quimioterapia nombre 0.555099 PDQ Acupuntura 0.392476 Instituto Nacional 0.371538	siguientes problemas 0.372583 siguientes factores 0.44966 Physician Data Query 0.449355 Lorazepam Benzodiazepinas 0.337793 vómitos tardíos 0.949937 siguientes características 0.461706 determinadas situaciones 0.34995 fosaprepitant antagonistas 0.342662 prometazina fenotiacinas 0.421253 PDQ Náuseas 0.567745 medicamento tipo 0.522815 flujo sanguíneo escaso 0.412994 haloperidol butirofenonas 0.346571	CLICK HERE
1953	National Cancer Institute	Html	es	Efectos tardíos del tratamiento anticanceroso en la niñez (PDQ®)–Versión para pacientes	Resumen de información revisada por expertos acerca de los problemas de salud que continúan o aparecen después de terminar un tratamiento de cáncer.	válvulas cardíacas 0.300344 digestivasLos efectos tardíos 0.301994 siguientes procedimientos 0.300445 células madre 0.31868 suficiente saliva 0.300202 adultos jóvenes 0.300215 tumor tipo 0.3006 leucemia linfocítica aguda 0.300977 leucemia linfoblástica aguda 0.303718 diabetes mellitus 0.300401 rayos x 0.300187 largo plazo 0.301433 alta densidad 0.300367 debilidad súbitos 0.300398 efectos tardíos 0.995697 luz solar 0.30049 tumores benignos 0.300573	siguientes maneras 0.300324 hormonas tiroideas 0.300415 antecedentes familiares 0.302575 revestimiento protector 0.300332 hepatitis b 0.300262 siguientes factores 0.300516 radiación uv 0.300991 topoisomerasa ii 0.300497 suficiente insulina 0.300239 cuerpo elabora insulina 0.300315 Radiografía panorámica 0.300213 leucemia mieloide aguda 0.302575 mandíbulasLos problemas 0.300385 cáncer infantil meses 0.303991 biliaresLos efectos tardíos 0.30194 Mayor tiempo 0.300312 siguientes pruebas 0.300654	CLICK HERE
2020	National Cancer Institute	Html	es	Prevención del cáncer de cuello uterino (PDQ®)–Versión para profesionales de salud	Sumario de información revisada por expertos sobre los factores que aumentarían el riesgo de presentar cáncer de cuello uterino y los enfoques que ayudarían a la prevención de esta enfermedad.	cervical intra-epithelial neoplasia 0.302624 Obstet Gynecol 0.303555 Lancet Infect Dis 0.302739 vacuna qHPV 0.302144 VPH vs 0.303877 cervical carcinoma 0.305011 cáncer invasor 0.318393 González A 0.303459 VPH oncógenos 0.304066 American Cancer Society 0.303348 case-control study 0.30305 Costa Rica Vaccine 0.302774 cervical neoplasia 0.303702 Schiffman M 0.30246 without cervical carcinoma 0.302609 risk factors 0.303566 collaborative reanalysis 0.305986 International Collaboration 0.302415 Estados Unidos 0.303742 vacuna 9vHPV 0.303595 cancer in 0.308272 Natl Cancer Inst 0.304144 cervical cancer 0.371053 vacuna vph 0.305378 North American multicohort 0.3021	9-valent hpv vaccine 0.303034 VPH Población Estimación 0.304092 Quadrivalent HPV Vaccination 0.302755 human papillomavirus 0.353991 vacuna nanovalente vlp 0.302596 risk among hiv-infected 0.30327 Bosch FX 0.30227 Castle PE 0.302445 Muñoz N 0.303856 Costa Rica 0.303541 collaboration prospective study 0.303065 Immune Defic Syndr 0.302422 multicohort collaboration prospective 0.302636 Adverse Pregnancy Outcomes 0.302449 Acquir Immune Defic 0.302422 epidemiological studies 0.313912 with cervical carcinoma 0.302983 vacuna vph-16 l1 0.302668 cervical intraepithelial neoplasia 0.304671 cuello uterino 0.985138 American multicohort collaboration 0.302442 Cancer In young 0.302413 vacuna bivalente tipo 0.302487 cancer risk 0.305603	CLICK HERE
2022	National Cancer Institute	Html	es	Exámenes de detección del cáncer de cuello uterino (PDQ®)–Versión para pacientes	Sumario de información revisada por expertos sobre los exámenes que se utilizan para detectar el cáncer de cuello uterino.	siguientes grupos 0.30039 PDQ Exámenes 0.300773 Physician Data Query 0.301635 libre uso 0.300195 cuello uterino 0.99515 prevención revisa 0.300275 largo plazo 0.300411	principal factor 0.302387 información ayuda 0.300455 National Cancer Institute 0.300349 siguientes riesgos 0.300249 siguientes sumarios 0.301285 Instituto Nacional 0.300751	CLICK HERE
2033	National Cancer Institute	Html	es	Prevención del cáncer de próstata (PDQ®)–Versión para profesionales de salud	Sumario de información revisada por expertos sobre los factores que pueden influir en el riesgo de cáncer de próstata y sobre la investigación dirigida a la prevención de esta enfermedad.	Thompson IM 0.314327 accessed july 0.302228 results from 0.303565 Connolly JM 0.303382 Prostate Cancer Events 0.317969 habitantes hombres 0.302425 Cancer Statistics Review 0.317133 Ross RK 0.305958 Sin embargo 0.309562 grasas animales 0.30255 American Cancer Society 0.316034 dietary fat 0.303757 tumores gleason 0.303142 productos lácteos 0.302873 Cancer Rates 0.308415 EI aumento 0.303513 EI riesgo 0.304572 Prostate specific 0.303323 Estados Unidos 0.302842 Natl Cancer Inst 0.462208 Gleason DF 0.304482 cancer prevention trial 0.348935 menor riesgo 0.303815 Prostate Cáncer Prevention 0.30803 SEER Cancer Statistics 0.317438	investigation into cancer 0.307885 Bernstein L 0.303522 prostate cancer prevention 0.326581 Prostate Prevention Trial 0.304615 Tangen CM 0.304256 Kristal AR 0.303247 EI Prostate Cancer 0.311391 United States 0.314913 Prostate Cancer Clinical 0.31207 Cancer Facts 0.309636 Kolonel LN 0.303682 prostate lncap tumors 0.303282 among japanese 0.304198 Nutr Cancer 0.308752 National Cancer Institute 0.326849 Epidemiol Biomarkers Prev 0.307319 dutasterida vs 0.303715 antecedentes familiares 0.303019 fatty acids 0.303826 Prostate Cancer Survey 0.310986 Prostate visualization studies 0.303528 grasas alimenticias 0.316785 prostate cancer 0.996017 Rose DP 0.305512	CLICK HERE
2049	National Cancer Institute	Html	es	Trasplantes de células madre formadoras de sangre	Hoja informativa que explica los procedimientos, paso a paso, del trasplante de médula ósea y del trasplante de células madre de sangre periférica, así como sus riesgos y beneficios.	células madre 0.995824 efecto gvt 0.300369 trasplante autólogo 0.304497 PBSCT alogénicos 0.300755 llamadas antígenos 0.300572 frecuencia células madre 0.306001 bone marrow transplantation 0.300883 raros casos 0.300403 Sin embargo 0.307734 catéter venoso central 0.300806 Programa Nacional 0.300971 llamadas células madre 0.30624 largo plazo 0.300324 causa disminución 0.300351 seguro médico 0.300814	cubre be 0.300325 paciente transfusiones 0.301172 HLA compatibles mejora 0.301344 idéntico.  sin embargo 0.300876 antígenos hla 0.303269 stem cell transplantation 0.300928 programa be 0.300461 posibles efectos 0.301054 linfocitos t".  0.3004 atacan.  más 0.300461 GVHD aguda 0.300451 corto plazo 0.30031 sangre.  solo 0.300435 usa dosis 0.301797 tipo hla 0.300841	CLICK HERE